Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle ...

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...

An experimental gene-silencing therapy safely lowered LRRK2 protein levels in an early Parkinson’s trial, but its effect on ...

Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...

Patients received either BIIB122 or a placebo for 48 to 144 weeks.

Mutations in the LRRK2 gene, which encodes the multidomain enzyme leucine-rich repeat kinase 2, represent one of the most common genetic contributors to Parkinson’s disease worldwide. The G2019S ...

NEW HAVEN, Conn., March 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, ...

High level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running ...

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the ...

(RTTNews) - Denali Therapeutics (DNLI), a biopharmaceutical company, on Thursday announced that the first participant has been dosed in its global Phase 2a BEACON study. BEACON study is a phase IIa ...

Shares of Denali Therapeutics, Inc. DNLI were down 8% in after-market trading on May 21, after the company and partner Biogen ...